Antipicornaviral compounds compositions containing them and methods for
申请人:Agouron Pharmaceuticals, Inc.
公开号:US06020371A1
公开(公告)日:2000-02-01
Picornaviral 3C protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the picornaviral 3C protease. These compounds, as well as pharmaceutical compositions that contain these compounds, are suitable for treating patients or hosts infected with one or more picornaviruses.
Design and synthesis of irreversible depsipeptidyl human rhinovirus 3C protease inhibitors
作者:Stephen E. Webber、Joseph T. Marakovits、Peter S. Dragovich、Thomas J. Prins、Ru Zhou、Shella A. Fuhrman、Amy K. Patick、David A. Matthews、Caroline A. Lee、Babu Srinivasan、Terry Moran、Clifford E. Ford、Mary A. Brothers、James E.V. Harr、James W. Meador、Rose Ann Ferre、Stephen T. Worland
DOI:10.1016/s0960-894x(01)00542-x
日期:2001.10
Novel tripeptidyl C-terminal Michael acceptors with an ester replacement of the P(2)-P(3) amidebond were investigated as irreversible inhibitors of the human rhinovirus (HRV) 3C protease (3CP). When screened against HRV serotype-14 the best compound was shown to have very good 3CP inhibition (k(obs)/[I]=270,000M(-1)s(-1)) and potent in vitro antiviral activity (EC(50)=7.0nM).
Antipicornaviral compounds, compositions containing them, and methods for their use
申请人:——
公开号:US20040072907A1
公开(公告)日:2004-04-15
A magnetic circuit component having a plurality of claws arranged in a plurality of rows, with the base of each claw connected to a common yoke. A plurality of non-interlaced coils constituting a multi-phase winding are included, with the coils being wound around the bases of corresponding claws, and being distributed uniformly in the direction of motion.
Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 2. Peptide Structure−Activity Studies
作者:Peter S. Dragovich、Stephen E. Webber、Robert E. Babine、Shella A. Fuhrman、Amy K. Patick、David A. Matthews、Siegfried H. Reich、Joseph T. Marakovits、Thomas J. Prins、Ru Zhou、Jayashree Tikhe、Ethel S. Littlefield、Ted M. Bleckman、Michael B. Wallace、Thomas L. Little、Clifford E. Ford、James W. Meador、Rose Ann Ferre、Edward L. Brown、Susan L. Binford、Dorothy M. DeLisle、Stephen T. Worland
DOI:10.1021/jm9800696
日期:1998.7.1
The structure-based design, chemical synthesis, and biological evaluation of various peptide-derived human rhinovirus (HRV) 3C protease (3CP) inhibitors are described. These compounds are comprised of an ethyl propenoate Michael acceptor moiety and a tripeptidyl binding determinant. The systematic modification of each amino acid residue present in the binding determinant as well as the N-terminal functionality is described. Such modifications are shown to provide irreversible HRV-14 3CP inhibitors with anti-3CP activities (k(obs)/[I]) ranging from 60 to 280 000 M-1 s(-1) and antiviral EC50's which approach 0.15 mu M. An optimized inhibitor which incorporates several improvements identified by the structure-activity studies is also described. This molecule displays very rapid irreversible inhibition of HRV-14 3CP (k(obs)/[I] = 800 000 M-1 s(-1)) and potent antiviral activity against HRV-14 in cell culture (EC50 = 0.056 mu M). A 1.9 Angstrom crystal structure of an S-alkylthiocarbamate-containing inhibitor complexed with HRV-8 3CP is also detailed.
INHIBITORS OF PICORNAVIRUS 3C PROTEASES AND METHODS FOR THEIR USE AND PREPARATION